These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6452036)

  • 41. Hypothalamic dysfunction in Parkinson's disease patients.
    Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
    Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
    Julien C; Berthiaume L; Hadj-Tahar A; Rajput AH; Bédard PJ; Di Paolo T; Julien P; Calon F
    Neurochem Int; 2006 Apr; 48(5):404-14. PubMed ID: 16442670
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
    Linazasoro G
    Arch Neurol; 2007 Jan; 64(1):137-40. PubMed ID: 17210824
    [No Abstract]   [Full Text] [Related]  

  • 44. The lack of dopaminergic effects on the motor responses produced by magnetic cortical stimulation in patients with Parkinson's disease.
    Nakashima K; Wang Y; Shimoda M; Sakuma K; Takahashi K
    Electromyogr Clin Neurophysiol; 1996; 36(7):433-7. PubMed ID: 8957169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
    Chang WY; Webster RA
    Br J Pharmacol; 1997 May; 121(2):331-7. PubMed ID: 9154345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical implications of sustained dopaminergic stimulation.
    Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
    Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 48. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relation of oxidative stress and hyperexcitation to neurological disease.
    Bondy SC
    Proc Soc Exp Biol Med; 1995 Apr; 208(4):337-45. PubMed ID: 7700883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxidative stress to dopaminergic neurons as models of Parkinson's disease.
    Gille G; Hung ST; Reichmann H; Rausch WD
    Ann N Y Acad Sci; 2004 Jun; 1018():533-40. PubMed ID: 15240412
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Neurology in 1977].
    Rosa A
    Rev Prat; 1977 Jun; 27(35):2215-20. PubMed ID: 143056
    [No Abstract]   [Full Text] [Related]  

  • 52. [Neural transplantations in the management of neurological diseases].
    Castrén E; Castrén M
    Duodecim; 2001; 117(14):1417-24. PubMed ID: 12181950
    [No Abstract]   [Full Text] [Related]  

  • 53. Transcranial magnetic stimulation in movement disorders.
    Berardelli A
    Electroencephalogr Clin Neurophysiol Suppl; 1999; 51():276-80. PubMed ID: 10590960
    [No Abstract]   [Full Text] [Related]  

  • 54. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Levodopa: rational and irrational pharmacology.
    Nutt JG
    Ann Neurol; 1994 Jul; 36(1):4-5. PubMed ID: 8024259
    [No Abstract]   [Full Text] [Related]  

  • 56. Molecular approaches to hereditary diseases of the nervous system: Huntington's disease as a paradigm.
    Wexler NS; Rose EA; Housman DE
    Annu Rev Neurosci; 1991; 14():503-29. PubMed ID: 1827708
    [No Abstract]   [Full Text] [Related]  

  • 57. Preface by the editors.
    Nguyen HH; Cenci MA
    Curr Top Behav Neurosci; 2015; 22():v-viii. PubMed ID: 26317142
    [No Abstract]   [Full Text] [Related]  

  • 58. Current conceptualizations of psychiatric illnesses as neurological disorders.
    Silverstein ML
    Mol Chem Neuropathol; 1990 Mar; 12(2):131-42. PubMed ID: 2149927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aging issues: neurological disorders: crosscutting breakout session. Physical Disabilities through the Lifespan Conference.
    Neurorehabil Neural Repair; 2005 Mar; 19(1 Suppl):70S-2S. PubMed ID: 15689478
    [No Abstract]   [Full Text] [Related]  

  • 60. Sexual functioning of persons with neurologic disorders.
    Strasberg PD; Brady SM
    Semin Neurol; 1988; 8(2):141-4. PubMed ID: 3187225
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.